一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (404k)
Article in Japanese

Case Report

A case of tuberculosis-associated immune reconstitution inflammatory syndrome for which early reintroduction of adalimumab and corticosteroid was effective

Yuki Fukushiroa,*  Yusuke Takayamaa  Shohei Mishimaa  Ken Masudaa  Hiroyasu Shodaa  Yasuo Iwamotob 

aDepartment of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
bDepartment of Oncology, Hiroshima City Hiroshima Citizens Hospital
*Present address: Department of Respiratory Medicine, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

ABSTRACT

A 49-year-old female with hidradenitis suppurativa under treatment with the tumor necrosis factor (TNF) α antagonist adalimumab was admitted to our hospital with tuberculosis (TB). We initiated anti-TB therapy (rifampicin, isoniazid, pyrazinamide, and ethambutol) and discontinued adalimumab. One month later, she developed chylothorax due to immune reconstitution inflammatory syndrome (IRIS). After we started corticosteroid (prednisolone 1.0 mg/kg/day as the initial dose) and resumed adalimumab for TB-IRIS, there was no re-accumulation of chylothorax. Finally, she completed a 9-month course of anti-TB therapy, and prednisolone was tapered off over the course of 9 months. In this case, the re-administration of a TNF α inhibitor with corticosteroid treatment was safe and effective for the management of TB-I

KEYWORDS

Adalimumab  Anti-tumor necrosis factor agent  Tuberculosis (TB)  Immune reconstitution inflammatory syndrome (IRIS)  Chylothorax 

Received 16 Jun 2022 / Accepted 22 Sep 2022

AJRS, 12(1): 29-33, 2023

Google Scholar